TP53 and breast carcinoma: Then, the Breast Cancer Gene-Expression Miner v4.7 resource, which integrated almost all public BC data comprising DNA microarrays and RNA-seq, was employed to evaluate CEMIP expression based on BC subtypes, patient age, nodal metastasis status, and TP53 mutation status again with 11,359 DNA microarrays.